Bristol-Myers Squibb's (BMY) Breyanzi Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM
Go back to Bristol-Myers Squibb's (BMY) Breyanzi Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 58.13 +2.32 (4.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.81 | 52 Week High | $77.12 | |||
| Open | $56.65 | 52 Week Low | $49.03 | |||
| Day High | $58.14 | P/E | 37.75 | |||
| Day Low | $56.41 | EPS | $1.54 | |||
| Volume | 10,003,974 | |||||
